Medical Home Products Divests of Subsidiary
Posted on: Friday, 7 October 2005, 09:00 CDT
Medical Home Products, Inc. (OTC:MHPT) announced today that it had sold its wholly owned subsidiary, Strictly Diabetics, Inc., a Medicare Durable Medical Equipment (DME) Provider.
Paul Mathis, the President and CEO of Medical Home Products, Inc., stated, "We believe that the sale of Strictly Diabetics, Inc. at this time will allow each company to concentrate on its core business and better serve its client base. This sale will reduce the debt load and increase the cash flow for Medical Home Products, allowing us to continue our rapid expansion into more profitable areas and increase our investor's Return on Investment (ROI)."
Medical Home Products, Inc. is an international resale provider of over 200 self-test medical kits sold via the internet and direct sales. Medical Home Products differentiates itself in the 2.82 Billion Dollar US self-test kit market by selling a comprehensive line of cross selection medical self-test kits for diabetes, cholesterol, DNA, fertility, HIV, mineral levels, pregnancy, prostate, thyroid, drug and alcohol testing. Medical Home Products operates a direct sales and virtual network to the worldwide home medical market, organized clinics and drug rehab facilities.
Medical Home Products, Inc., http://www.medicalhomeproducts.com, is publicly traded on the OTC under the symbol MHPT with headquarters in St. Petersburg, Fla.
This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan,""expect,""believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets.
Source: Business Wire
Related Articles
- Magnum Initiates Full Production of Diversified Product Materials, Schedules Executive Appearances, and Releases Market Updates on Magnum/SRI Division
- Power3 Medical Products in Talks With Industry Leaders to License and Market Its Proprietary Technology for Diagnostic, Disease Detection Blood Tests for Breast Cancer, Alzheimer's and Parkinson's Disease
- Power3 Medical Products to Market Diagnostic Tests
- Power3 Medical Products, Inc. Makes Its Diagnostic Tests Ready for Commercialization
- Power3 Medical Products Announces New Collaboration for Breast Cancer Test
- Power3 Medical Products and the Princess Haya Biotechnology Center, Jordan University of Science and Technology, Collaborate in a Clinical Validation Study of the BC-SeraPro(TM) Breast Cancer Diagnostic Blood Test
- Power3 Medical Products, Inc. Launches BC-SeraPro, the First Proteomics-Based Blood Serum Diagnostic Test for Breast Cancer
- Power3 Medical Products, Inc. Announces Preliminary International Validation Results of Their Blood Serum Biomarker Test for Parkinson's Diseases
- 900 Jobs to Be Cut in Medical Products: Abbott, Hospira Cite Need to Reduce Costs
- Logic Product Development Releases Low-Cost Development Kit Based on the Intel(R) PXA270 Processor and Production-Ready Solutions for Reduced Time to Market
 |
 |
User Comments (0)
RSS Feeds